NeuClone Reveals Rivals To Opdivo And Keytruda
Australian Biosimilars Specialist Is Developing Nivolumab And Pembrolizumab
Executive Summary
Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.